Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation.

Fusheng Li1, Uma Malhotra, Peter B Gilbert

  • 1Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

Vaccine
|August 8, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Overexpression of the EfMYB124 gene from Erianthus fulvus enhances tolerance to low temperature and drought in Arabidopsis thaliana.

BMC plant biology·2026
Same author

Occurrence of antibiotic resistance genes and potential drivers of their persistence in tap water from well-managed drinking water systems.

Environmental science and pollution research international·2026
Same author

The prevalence and associations of stroke history with self-reported sleep disturbances in China: a nationwide cross-sectional study.

BMC public health·2026
Same author

Silver-loaded granular activated carbon for fixed-bed drinking water treatment: antibacterial effect in both water and biofilm phases and impact on organic matter removal.

Chemosphere·2026
Same author

p-Block Antimony Single-Atom Tuned Copper Sites for Boosting Electrocatalytic Semi-Hydrogenation of 2-methyl-3-butyn-2-ol.

Angewandte Chemie (International ed. in English)·2026
Same author

Rhizobacteria-Mediated Plant Resilience to Abiotic Stresses: Drought, Salinity, and Heat.

Plant, cell & environment·2026

Developing standardized peptide reagents for human immunodeficiency virus-type 1 (HIV-1) vaccines is crucial. A biometric approach identified vaccine-important epitopes (VIPs) from circulating strains, enabling better T-cell response evaluation.

Area of Science:

  • Immunology
  • Virology
  • Vaccinology

Background:

  • Dozens of human immunodeficiency virus-type 1 (HIV-1) vaccine candidates targeting cytotoxic T-lymphocyte (CTL) responses are in clinical trials.
  • Evaluating HIV-1 vaccine efficacy is difficult due to the extensive genetic diversity of circulating viral strains.
  • Standardized peptide reagents are needed to accurately assess T-cell responses against diverse HIV-1 strains.

Purpose of the Study:

  • To develop a novel biometric approach for defining standardized peptide reagents for HIV-1 vaccine evaluation.
  • To identify and select a common panel of HIV-1 peptides based on prevalent circulating strains for CTL-based vaccine assessment.

Main Methods:

  • A biometric approach utilizing T-cell recognition patterns was developed to define standardized reagents.

Related Experiment Videos

  • Analysis of circulating HIV-1 strains from the Los Alamos database.
  • Generation of standardized algorithms to identify all potential T-cell epitopes (PTEs).
  • Selection of vaccine-important PTEs (VIPs) based on prevalence in circulating strains.

    • Main Results:

    • A finite set of VIPs was identified from the evaluated PTEs.
    • A common standardized panel of HIV-1 peptides was selected for CTL-based vaccine evaluation.
    • The utility of the PTE peptide set was demonstrated by detecting Nef-specific CTL responses in HIV-1 subtype B infections.

    Conclusions:

    • The developed biometric approach successfully identified VIPs for creating standardized HIV-1 peptide reagents.
    • The selected peptide panel is a valuable tool for evaluating CTL-based HIV-1 vaccines against diverse strains.
    • This methodology aids in assessing vaccine immunogenicity and potential efficacy in the context of global HIV-1 genetic diversity.